---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003881"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T08:27:53.668943+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Corvus Pharmaceuticals 2025 Annual Meeting results: all proposals approved

## Summary
- Elected Class III directors Ian T. Clark (28.9M for, 10.4M withheld) and Peter A. Thompson (38.8M for, 0.4M withheld).
- Ratified PricewaterhouseCoopers as independent auditor for FY2025: 53.1M for, 0.1M against, 0.1M abstain.
- Non-binding advisory vote on named executive officer compensation passed: 37.1M for, 2.1M against, 63.8k abstain.
- 53.4M shares voted of 68.2M outstanding; broker non-votes of 14.1M on director and compensation proposals.

## SEC filing metadata
- accession: 0001171843-25-003881
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184325003881/0001171843-25-003881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184325003881/f8k_061325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003881
- JSON: https://secwatch.observer/filing/0001171843-25-003881.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.